Trimedyne (OTC BB: TMED) CEO Interview

This interview has expired.
Click here to find stocks, with exciting stories, and management committed to maximizing shareholder value.

Special deals for our readers
Are you qualified for the Visa Black Card?
The World’s Most Prestigious and Versatile Credit Card. Apply Now!

Be a more profitable investor:
What’s Jim Cramer trading in his personal portfolio? Click here

Get an Equifax 3-in-1 Credit Report Now!

Why are you still paying too much with Schwab, and and E-trade?? Step up to the #1 discount broker: TradeKing.
Find out why was ranked #1 Discount Broker by SmartMoney Magazine two years running! (August 2006 & 2007).

Invest Smarter! Get 4 Bonus Weeks of Investor’s Business Daily Digital Edition!

LifeLock is the only Identity Theft Prevention Solution backed by a one-million dollar guarantee!Click here to get a 10% discount.

Get FICO Score Watch Now!

Free Quicken Online automatically categorizes your expenses.

Click here to get access to powerful investing tools only available at Investor’s Business Daily.

Get a free look at Jim Cramer’s Action Alerts PLUS portfolio. Click here

Dr. Marvin Loeb, CEO

Trimedyne, Inc. is engaged in the development, manufacturing and marketing of 80 and 30 watt Holmium cold pulsed lasers (Lasers) and a variety of disposable and reusable, fiber optic laser energy delivery devices (fibers, needles and tips) for use in an array of medical applications. The lasers, fibers, needles and tips have been cleared for sale by the United States Food and Drug Administration (FDA) for use in orthopedics, urology, ear, nose and throat (ENT) surgery, gynecology, gastrointestinal surgery, general surgery and other medical specialties. The Company’s wholly owned subsidiary Mobile Surgical Technologies, Inc. is engaged in the rental of lasers, along with the services of a trained operator and the provision of applicable fibers, needles or tips, on a fee per case basis to hospitals, surgery centers, group practices and individual physicians in Texas.

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.